Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Healthcare | Pharmaceuticals | ARS 749.30T | 62.3x | 0.61 | ARS 15,475 | -7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 421.56T | 17x | -0.45 | ARS 12,100 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 421.56T | 17x | ARS 1,300 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Johnson & Johnson | Buenos Aires | Healthcare | Pharmaceuticals | ARS 392.70T | 26x | -1.38 | ARS 815 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Buenos Aires | Healthcare | Pharmaceuticals | ARS 342.89T | 70.9x | -6.02 | ARS 20,150 | -8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 248.11T | 29.9x | 1.59 | ARS 39,425 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 246.40T | 18.6x | -0.97 | ARS 32,450 | -5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 218.70T | 11.3x | 0 | ARS 17,925 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Buenos Aires | Healthcare | Pharmaceuticals | ARS 172.64T | 37.1x | -0.95 | ARS 11,200 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Buenos Aires | Healthcare | Pharmaceuticals | ARS 148.86T | 276.3x | -2.94 | ARS 30,825 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 142.05T | 15.5x | 0.05 | ARS 6,470 | -7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 113.44T | -11.2x | 0.05 | ARS 19,500 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 84.89T | 21.3x | -0.42 | ARS 10,525 | -5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | Buenos Aires | Healthcare | Pharmaceuticals | ARS 36.90T | 24.7x | 0.26 | ARS 53,500 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen AR | Buenos Aires | Healthcare | Pharmaceuticals | ARS 19.24T | 10.3x | 0.26 | ARS 10,500 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorios Richmond | Buenos Aires | Healthcare | Pharmaceuticals | ARS 117.90B | 4.9x | 0.02 | ARS 1,460 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Instituto Rosenbusch | Buenos Aires | Healthcare | Pharmaceuticals | ARS 3.56B | -2.5x | 0.22 | ARS 83.50 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |